OCC Trading, page-1664

I have been selling down based on the slow (at least IMO) revenues to date. Agree that there should be a re-rate on US approval but unless sales accelerate there will be another 6-9 months of waiting. I’d rather re-invest these days when it’s approved. The slow steady progress is fine for staff and board but it’s an opportunity cost for retail holders. Also see the uptake of new technology doesn’t always happen in the medical field as many are set in their ways. It will take some push from OCC to accelerate uptake. Safe hold but there may be better opportunities. GLTA